OBJECTIVE: The HLA-B27/β2 -microglobulin (β2 m)-transgenic (Tg) rat is a leading model of B27-associated spondyloarthritis (SpA), and the disease is dependent on the presence of intestinal bacteria. Previous studies have shown that adult HLA-B27/β2 m-Tg rats have an altered intestinal microbiota. This study sought to better define the age-dependent changes to both mucosal immune function and dysbiosis in this rat model of SpA. METHODS: Intestinal contents were collected from wild-type and HLA-B27/β2 m-Tg rats postweaning (ages 3 and 6 weeks), at disease onset (age 10 weeks), and after the establishment of disease (ages ≥16 weeks). The microbial community structure was determined by 16S ribosomal RNA sequencing and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Mucosal and systemic Th1, Th17, and Treg cell responses were analyzed by flow cytometry, as was the frequency of IgA-coated intestinal bacteria. Intestinal expression of inflammatory cytokines and antimicrobial peptides (AMPs) was determined by qRT-PCR. RESULTS: An inflammatory cytokine signature and elevated AMP expression during the postweaning period preceded the development of clinical bowel inflammation and dysbiosis in HLA-B27/β2 m-Tg rats. An early and sustained expansion of the Th17 cell pool was specifically observed in the cecal and colonic mucosa of HLA-B27/β2 m-Tg rats. Strongly elevated intestinal colonization of Akkermansia muciniphila and an increased frequency of IgA-coated fecal bacteria were significantly associated with expression of HLA-B27 and arthritis development. CONCLUSION: HLA-B27/β2 m expression in this rat model renders the host hyperresponsive to microbial antigens from infancy. Early activation of innate immunity and expansion of a mucosal Th17 signature are soon followed by dysbiosis in HLA-B27/β2 m-Tg animals. The pathologic processes of perturbed mucosal immunity and dysbiosis strongly merit further study in both prediseased and diseased populations of patients with SpA.
OBJECTIVE: The HLA-B27/β2 -microglobulin (β2 m)-transgenic (Tg) rat is a leading model of B27-associated spondyloarthritis (SpA), and the disease is dependent on the presence of intestinal bacteria. Previous studies have shown that adult HLA-B27/β2 m-Tg rats have an altered intestinal microbiota. This study sought to better define the age-dependent changes to both mucosal immune function and dysbiosis in this rat model of SpA. METHODS: Intestinal contents were collected from wild-type and HLA-B27/β2 m-Tg rats postweaning (ages 3 and 6 weeks), at disease onset (age 10 weeks), and after the establishment of disease (ages ≥16 weeks). The microbial community structure was determined by 16S ribosomal RNA sequencing and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Mucosal and systemic Th1, Th17, and Treg cell responses were analyzed by flow cytometry, as was the frequency of IgA-coated intestinal bacteria. Intestinal expression of inflammatory cytokines and antimicrobial peptides (AMPs) was determined by qRT-PCR. RESULTS: An inflammatory cytokine signature and elevated AMP expression during the postweaning period preceded the development of clinical bowel inflammation and dysbiosis in HLA-B27/β2 m-Tg rats. An early and sustained expansion of the Th17 cell pool was specifically observed in the cecal and colonic mucosa of HLA-B27/β2 m-Tg rats. Strongly elevated intestinal colonization of Akkermansia muciniphila and an increased frequency of IgA-coated fecal bacteria were significantly associated with expression of HLA-B27 and arthritis development. CONCLUSION:HLA-B27/β2 m expression in this rat model renders the host hyperresponsive to microbial antigens from infancy. Early activation of innate immunity and expansion of a mucosal Th17 signature are soon followed by dysbiosis in HLA-B27/β2 m-Tg animals. The pathologic processes of perturbed mucosal immunity and dysbiosis strongly merit further study in both prediseased and diseased populations of patients with SpA.
Authors: Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie Journal: Immunity Date: 2006-08 Impact factor: 31.745
Authors: Mary-Ellen Costello; Francesco Ciccia; Dana Willner; Nicole Warrington; Philip C Robinson; Brooke Gardiner; Mhairi Marshall; Tony J Kenna; Giovanni Triolo; Matthew A Brown Journal: Arthritis Rheumatol Date: 2015-03 Impact factor: 10.995
Authors: M Faure; D Moënnoz; C Mettraux; F Montigon; E J Schiffrin; C Obled; D Breuillé; J Boza Journal: Dig Dis Sci Date: 2004-02 Impact factor: 3.199
Authors: Duke Geem; Oscar Medina-Contreras; Michelle McBride; Rodney D Newberry; Pandelakis A Koni; Timothy L Denning Journal: J Immunol Date: 2014-06-04 Impact factor: 5.422
Authors: Xochitl C Morgan; Boyko Kabakchiev; Levi Waldron; Andrea D Tyler; Timothy L Tickle; Raquel Milgrom; Joanne M Stempak; Dirk Gevers; Ramnik J Xavier; Mark S Silverberg; Curtis Huttenhower Journal: Genome Biol Date: 2015-04-08 Impact factor: 13.583
Authors: Mark Asquith; Sean Davin; Patrick Stauffer; Claire Michell; Cathleen Janowitz; Phoebe Lin; Joe Ensign-Lewis; Jason M Kinchen; Dennis R Koop; James T Rosenbaum Journal: Arthritis Rheumatol Date: 2017-08-31 Impact factor: 10.995
Authors: Tejpal Gill; Mark Asquith; Stephen R Brooks; James T Rosenbaum; Robert A Colbert Journal: Arthritis Rheumatol Date: 2018-03-07 Impact factor: 10.995
Authors: J Magarian Blander; Randy S Longman; Iliyan D Iliev; Gregory F Sonnenberg; David Artis Journal: Nat Immunol Date: 2017-07-19 Impact factor: 25.606